LAB vs TMO
LAB: Standard BioTools provides specialized proteomics and genomics research platforms to accelerate drug discovery, currently undergoing a strategic transition toward a merger with Treeline Biosciences. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | LAB | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $0.6373 | $687.37 | |
| Market cap | $250M | $254.2B | |
| P/E as of 2026-10-20 | 2.90 | 37.00 | LAB lower |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | n/a | 178.25 | |
| Net margin FY2025, SEC XBRL | -87.8% | +15.0% | TMO higher |
| Gross margin FY2025, SEC XBRL | +49.9% | n/a | |
| Operating margin FY2025, SEC XBRL | -129.2% | +17.4% | TMO higher |
| ROE FY2025, SEC XBRL | -17.7% | +12.6% | TMO higher |
| ROA FY2025, SEC XBRL | -13.2% | +6.1% | TMO higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-27 | n/a | 0.87 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -6.2% | +3.9% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | -4.5% | -0.3% | TMO higher |
| Dividend yield as of 2026-09-02 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | TMO higher |
| Beta as of 2026-09-02 | 1.46 | 0.77 | |
| 1-year return as of 2026-10-20 close | -50.2% | +26.4% | TMO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.